AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9429915 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on Eating and Weight Patterns (QEWP)
Number of subjects: 128
Study 9429915 — intervention group
Group type: COMPARATOR
Intervention: Binge Eating Scale (BES) and Questionnaire on Eating and Weight Patterns (QEWP)
Number of subjects: 128
Study 8051319 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate stick
Number of subjects: 70
Study 8051319 — intervention group
Group type: COMPARATOR
Intervention: Black ink (Control)
Number of subjects: 70
Study 3132225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology screening
Number of subjects: 200
Study 3132225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology and colposcopy screening
Number of subjects: 200
Study 3132225 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller lesions not detected by cytology screening
Number of subjects: 200
Study 31739213 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology (8-min for each foot, total 16 min)
Number of subjects: 120
Study 31739213 — intervention group
Group type: COMPARATOR
Intervention: Routine post-angiography care services (Control)
Number of subjects: 120
Study 29931358 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg (2400 IU)/d of D3
Number of subjects: 35
Study 29931358 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/d of 25(OH)D3
Number of subjects: 35
Study 29931358 — intervention group
Group type: COMPARATOR
Intervention: Both D3 and 25(OH)D3 groups combined
Number of subjects: 35
Study 28835238 — intervention group
Group type: EXPERIMENTAL
Intervention: STarT Back Tool (STarT) questionnaire
Number of subjects: 475
Study 28835238 — intervention group
Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 475
Study 26338971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar with planned thienopyridine
Number of subjects: 16449
Study 26338971 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar without planned thienopyridine
Number of subjects: 16449
Study 23154532 — intervention group
Group type: EXPERIMENTAL
Intervention: Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 29
Study 23154532 — intervention group
Group type: COMPARATOR
Intervention: Normal saline based on insulin intensive therapy
Number of subjects: 29
Study 21601549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled internal jugular vein catheters (TIJC) with taurolidine lock
Number of subjects: 0
Study 21601549 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 0
Study 21601549 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF) failure patients
Number of subjects: 0
Study 21601549 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF) success patients
Number of subjects: 0
Study 17383202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion instructions with reward
Number of subjects: 0
Study 17383202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion instructions with noise added to sequences
Number of subjects: 0
Study 17383202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion instructions with shortened training
Number of subjects: 0
Study 12814155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuttle walk test (SWT) on a conventional corridor
Number of subjects: 20
Study 12814155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuttle walk test (SWT) on a programmable treadmill
Number of subjects: 20
Study 12814155 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill equivalent SWT
Number of subjects: 20
Study 12814155 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PaO2
Number of subjects: 20
Study 12814155 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO
Number of subjects: 20
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian patients with HCC
Number of subjects: 76
Study 10223232 — intervention group
Group type: COMPARATOR
Intervention: Non-Asian patients with HCC
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with resectable tumors
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alpha-fetoprotein level <10 ng/mL
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at diagnosis
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor resectability and non-Asian race
Number of subjects: 76
Study 10223232 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for multiple variables
Number of subjects: 76
Study 8566739 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salicylate (IS)
Number of subjects: 67
Study 2360836 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser pulses (694 nm, 40 to 80 nanoseconds) at a fluence of 1.5 to 8.0 J/cm2
Number of subjects: 57
Study 2360836 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser pulses (694 nm, 40 to 80 nanoseconds)
Number of subjects: 57
Study 227433 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 36‐984 (nomifensine)
Number of subjects: 0
Study 227433 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil)
Number of subjects: 0
Study 227433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29742746 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected high-intensity interval exercise (HIIESS)
Number of subjects: 14
Study 29742746 — intervention group
Group type: COMPARATOR
Intervention: Imposed high-intensity interval exercise (HIIEIMP)
Number of subjects: 14
Study 28698075 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500mg/day) with Clomiphene citrate (100mg/day)
Number of subjects: 108
Study 28698075 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) (1800mg/day) with Clomiphene citrate (100mg/day)
Number of subjects: 108
Study 28698075 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 108
Study 28698075 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 108
Study 25573882 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-tertile ACR group
Number of subjects: 445
Study 23657509 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with exercises
Number of subjects: 100
Study 23657509 — intervention group
Group type: COMPARATOR
Intervention: Control group (orientation program)
Number of subjects: 100
Study 20727236 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Plus+® (dietary supplement from fruits and vegetables)
Number of subjects: 529
Study 20727236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 19165198 — intervention group
Group type: COMPARATOR
Intervention: Standard AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 3 weeks)
Number of subjects: 126
Study 19165198 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 2 weeks with pegfilgrastim)
Number of subjects: 126
Study 19165198 — intervention group
Group type: COMPARATOR
Intervention: Combined standard and accelerated AC
Number of subjects: 126
Study 19165198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EC (epirubicin 90 mg m(‐2) every 3 weeks or every 2 weeks with pegfilgrastim)
Number of subjects: 126
Study 19165198 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated AC and EC with pegfilgrastim
Number of subjects: 126
Study 19165198 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated treatment
Number of subjects: 126
Study 17956455 — intervention group
Group type: COMPARATOR
Intervention: Sulodexide given over 26 weeks in the Microalbuminuria Trial
Number of subjects: 3240
Study 17956455 — intervention group
Group type: COMPARATOR
Intervention: Sulodexide in the Overt Nephropathy Trial
Number of subjects: 3240
Study 14505238 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of parenteral Cefazolin preoperatively
Number of subjects: 99
Study 14505238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 11704087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Cu-375 SL IUD
Number of subjects: 1013
Study 9022487 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin and heparin (5000 U of unfractionated heparin subcutaneously 12 hourly)
Number of subjects: 90
Study 9022487 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (75 mg daily)
Number of subjects: 90
Study 7939147 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional views (Caldwell's and Waters' views)
Number of subjects: 0
Study 7939147 — intervention group
Group type: COMPARATOR
Intervention: Coronal CT scans
Number of subjects: 0
Study 29926217 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lenalidomide capsule (25 mg)
Number of subjects: 48
Study 29926217 — intervention group
Group type: COMPARATOR
Intervention: Revlimid® capsule (25 mg)
Number of subjects: 48
Study 27262965 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based combined alcohol use and sexual assault risk reduction intervention
Number of subjects: 264
Study 27262965 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-only intervention
Number of subjects: 264
Study 27262965 — intervention group
Group type: COMPARATOR
Intervention: Sexual assault-only intervention
Number of subjects: 264
Study 27262965 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based combined intervention
Number of subjects: 264
Study 23929423 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 353
Study 23929423 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 353
Study 22769732 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparo-endoscopic single-site surgery (LESS)
Number of subjects: 40
Study 22769732 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 40
Study 22769732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20540943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 48
Study 20540943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TSST)
Number of subjects: 48
Study 19842347 — intervention group
Group type: EXPERIMENTAL
Intervention: Notched noise stimuli (windowed sound therapy [WST])
Number of subjects: 0
Study 19842347 — intervention group
Group type: COMPARATOR
Intervention: Non-notched broadband noise
Number of subjects: 0
Study 19842347 — intervention group
Group type: COMPARATOR
Intervention: Noise of water
Number of subjects: 0
Study 16784745 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device
Number of subjects: 0
Study 16784745 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 0
Study 15468963 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA alone (2-3 mg/kg/d)
Number of subjects: 36
Study 15468963 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA after intravenous pulse methylprednisolone therapy (CsA/PMT) (2-3 mg/kg/d)
Number of subjects: 36
Study 15468963 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (PSL, 40-60 mg/d)
Number of subjects: 36
Study 10946808 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 40
Study 10946808 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 40
Study 10946808 — intervention group
Group type: COMPARATOR
Intervention: CRRT (both CVVH and CVVHDF)
Number of subjects: 40
Study 9309990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (5, 10, 20, or 40 mg to a cumulative dose of 635 mg)
Number of subjects: 43
Study 9309990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (first challenge)
Number of subjects: 43
Study 9309990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (second challenge)
Number of subjects: 43
Study 9309990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol inhalation
Number of subjects: 43
Study 9309990 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation
Number of subjects: 43
Study 8100421 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU IFN-alpha A for 6 weeks
Number of subjects: 8
Study 8100421 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% albumin for 6 weeks
Number of subjects: 8
Study 8100421 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline for 6 weeks
Number of subjects: 8
Study 8100421 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 8
Study 3105565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 60
Study 3105565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31522954 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative nursing care
Number of subjects: 28
Study 31522954 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 28
Study 30786829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg/day)
Number of subjects: 58
Study 30786829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27282852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambrosol Trio (biocompatible PD solution)
Number of subjects: 101
Study 27282852 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solution (Dianeal)
Number of subjects: 101
Study 27282852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambrosol Trio
Number of subjects: 101
Study 27282852 — intervention group
Group type: COMPARATOR
Intervention: Gambrosol Trio and Standard PD solution
Number of subjects: 101
Study 24323166 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl
Number of subjects: 60
Study 24323166 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl and dexamethasone sodium phosphate
Number of subjects: 60
Study 24323166 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 60
Study 24323166 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine and dexamethasone sodium phosphate
Number of subjects: 60
Study 22652561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy (AgPT)
Number of subjects: 1974
Study 22652561 — intervention group
Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 1974
Study 20417925 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered 3 days prior to surgery (Group 1, n = 5)
Number of subjects: 10
Study 20417925 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the time of surgery (Group 2, n = 5)
Number of subjects: 10
Study 20417925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 18605454 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluoride varnish
Number of subjects: 150
Study 18605454 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluoride varnish
Number of subjects: 150
Study 18605454 — intervention group
Group type: COMPARATOR
Intervention: 0.5% sodium fluoride
Number of subjects: 150
Study 18605454 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 150
Study 16003294 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d of simvastatin
Number of subjects: 48
Study 16003294 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d of atorvastatin
Number of subjects: 48
Study 16003294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12142826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding compression hip screw (Dynamic Hip Screw; Synthes‐Stratec, Oberdorf, Switzerland)
Number of subjects: 206
Study 12142826 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nail (Proximal Femoral Nail; Synthes‐Stratec, Oberdorf, Switzerland)
Number of subjects: 206
Study 10350666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive elderly patients
Number of subjects: 26
Study 10350666 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly subjects (Control)
Number of subjects: 26
Study 7549167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 2 micrograms/ml fentanyl via PCEA
Number of subjects: 41
Study 7549167 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine with 2 micrograms/ml fentanyl via continuous epidural infusion (CEI)
Number of subjects: 41
Study 1940776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (3 g daily)
Number of subjects: 31
Study 1940776 — intervention group
Group type: COMPARATOR
Intervention: Acipimox (0.75 g daily)
Number of subjects: 31
Study 6779890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (4 mg)
Number of subjects: 17
Study 6779890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational powder (400 micrograms)
Number of subjects: 17
Study 6779890 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (4 mg)
Number of subjects: 17
Study 6779890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31395485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) at a dose of 2 mg kg‐1 IV and then IM
Number of subjects: 16
Study 31395485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) at a dose of 4 mg kg‐1 IV
Number of subjects: 16
Study 31395485 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 28618772 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of pitavastatin
Number of subjects: 1101
Study 28618772 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of pitavastatin
Number of subjects: 1101
Study 26563757 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-Led Introduction to SolidS (BLISS) intervention with additional parent contacts (n=8) for support and education from before birth to 12 months of age.
Number of subjects: 200
Study 26563757 — intervention group
Group type: COMPARATOR
Intervention: Standard Well Child care provided to all parents in New Zealand (Control group).
Number of subjects: 200
Study 22975753 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL13 (BCA-1)
Number of subjects: 186
Study 22975753 — intervention group
Group type: EXPERIMENTAL
Intervention: matrix metalloproteinase-3 (MMP-3)
Number of subjects: 186
Study 22975753 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue inhibitor of metalloproteinases-1 (TIMP-1)
Number of subjects: 186
Study 22975753 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 186
Study 22975753 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 186
Study 21251383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway anaesthesia combined with sacral canal block
Number of subjects: 60
Study 21251383 — intervention group
Group type: COMPARATOR
Intervention: Single tracheal tube anaesthesia
Number of subjects: 60
Study 19549331 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim monitoring and modification of recruitment strategies
Number of subjects: 1644
Study 19549331 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of HIV
Number of subjects: 1644
Study 19549331 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies based on interim analyses
Number of subjects: 1644
Study 17462615 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg) and ambroxol HCl (30 mg) dispersible tablet (treatment A)
Number of subjects: 12
Study 17462615 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg roxithromycin dispersible tablet and 30 mg ambroxol HCl tablet (treatment B)
Number of subjects: 12
Study 17462615 — intervention group
Group type: COMPARATOR
Intervention: 150 mg roxithromycin dispersible tablet (treatment C)
Number of subjects: 12
Study 17462615 — intervention group
Group type: COMPARATOR
Intervention: 30 mg ambroxol HCl tablet (treatment D)
Number of subjects: 12
Study 15614648 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS group (ventral minimal invasive approach)
Number of subjects: 50
Study 15614648 — intervention group
Group type: COMPARATOR
Intervention: Standard group (anterolateral transgluteal approach)
Number of subjects: 50
Study 11296098 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (150 microg)
Number of subjects: 18
Study 11296098 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 11296098 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 administration
Number of subjects: 18
Study 9247907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with diet and exercise
Number of subjects: 4000
Study 9247907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage) with standard diet and exercise
Number of subjects: 4000
Study 9247907 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (investigational drug) with standard diet and exercise
Number of subjects: 4000
Study 9247907 — intervention group
Group type: COMPARATOR
Intervention: Trivalent chromium (not included in the program)
Number of subjects: 4000
Study 8290882 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum (3.6 mg, four times daily)
Number of subjects: 32
Study 8290882 — intervention group
Group type: COMPARATOR
Intervention: Miconazole gel (50 mg, four times daily)
Number of subjects: 32
Study 8290882 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum
Number of subjects: 32
Study 8290882 — intervention group
Group type: COMPARATOR
Intervention: Miconazole gel
Number of subjects: 32
Study 3326678 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 105
Study 3326678 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 105
Study 3326678 — intervention group
Group type: COMPARATOR
Intervention: Buffered aspirin 600 mg
Number of subjects: 105
Study 3326678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105